IPO
The Company and its wholly owned subsidiary, Motif BioSciences Inc., have entered into a loan Amendment and Release agreement with Hercules Capital Inc., the senior secured lender to Motif Inc, regarding certain actions which fully satisfy the conditions attached to the Company’s previously announced agreement in principle with Hercules
CYNBIOME receives funding under Investments for the Future Program (PiA), supplemented by €3M ($3.3M) of Cynbiose’s own funds
PDC*line Pharma announces the completion of its Series B round of financing.
iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the closing of a EUR 15 million Series A financing.
Heidelberg Pharma AG announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany
Voluntary public share buyback offer against cash payment in a purchase price range of EUR 1.60 to EUR 1.85 per share
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models
Sensyne Health plc, the British Clinical AI technology company, announces its Interim Results for the 6 months ended 31 October 2019.
Evotec SE announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company’s financial performance.
The funds will allow the company to accelerate the development of its chemotherapy drug candidate targeting solid tumors
PRESS RELEASES